Juvenescence advances aging drug to Phase 2 trial
Juvenescence reported completion of a Phase 1 trial of its first-in-class PAI-1 inhibitor MDI-2517, demonstrating safety, tolerability, and once-daily oral dosing. The company plans Phase 2 trials in 2026 focusing on metabolic and fibrotic diseases. Senior hires from GSK and experienced clinical development leaders were appointed as the AI-enabled biotech advances additional age-related programs toward clinical testing.
Why it mattersCompletion of MDI-2517's Phase 1 trial enables Phase 2 trials in 2026 addressing fibrotic and metabolic disease.
Entities Mentioned
GSK
People Mentioned
Kyle Umipig